Avalyn Pharma Inc. (AVLN)

Avalyn Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Selling, General & Admin	14.68	9.96
Research & Development	76.61	45.76
Operating Expenses	91.29	55.72
Operating Income	-91.29	-55.72
Interest & Investment Income	6.18	7.44
Other Non Operating Income (Expenses)	-0.09	-0.02
EBT Excluding Unusual Items	-85.2	-48.3
Gain (Loss) on Sale of Assets	-	-0.05
Legal Settlements	-	-1.4
Pretax Income	-85.2	-49.74
Net Income	-85.2	-49.74
Net Income to Common	-85.2	-49.74
Shares Outstanding (Basic)	19	5
Shares Outstanding (Diluted)	19	5
Shares Change (YoY)	259.46%	-
EPS (Basic)	-4.56	-9.57
EPS (Diluted)	-4.56	-9.57
Free Cash Flow	-81.83	-48.46
Free Cash Flow Per Share	-4.38	-9.32
EBITDA	-91.25	-55.69
D&A For EBITDA	0.04	0.03
EBIT	-91.29	-55.72

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q